APA (7th ed.) Citation

S, S., A, P., FG, H., P, G., Y, X., AH, P., . . . M, B. (2026). A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". Dermatology and therapy, 16(2), 1433. https://doi.org/10.1007/s13555-025-01627-4

Chicago Style (17th ed.) Citation

S, Ständer, et al. "A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"." Dermatology and Therapy 16, no. 2 (2026): 1433. https://doi.org/10.1007/s13555-025-01627-4.

MLA (9th ed.) Citation

S, Ständer, et al. "A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"." Dermatology and Therapy, vol. 16, no. 2, 2026, p. 1433, https://doi.org/10.1007/s13555-025-01627-4.